GW Pharmaceuticals and Otsuka Announce Results From Two Remaining Sativex(R) Phase 3 Cancer Pain Trials
- Consistent with previously announced results from the initial Phase 3 trial, remaining trials fail to show superiority over placebo - - Pre-specified subgroup analyses of pooled U.S. patients demonstrated a statistically significant result for the …